Merle P, Blanc J-F, Phelip J-M, et al, on behalf of the RELIVE Investigators. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 2019; 4: 454–65—The appendix for this Article has been updated. This correction has been made to the online version as of June 3, 2019.
All Science Journal Classification (ASJC) codes